RheumNow Podcast – The Shoes Maketh the Doctor (10.25.19) Save

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.

1. FDA has set a new record for generic-drug approvals in 2019, with new 1,171 generic drugs (ws 971 in 2018 & 937 in 2017). HHS Secretary Alex Azar praised FDA for 3 record-setting yrs of improving prices & consumer access to prescription drugs. https://t.co/XQ2Etl6g72
2. Observational study of the meditteranean diet on 211 Psoriatic Arthritis patients. 27% had MetSyndr. Moderate adherence 66%. Disease activity (DAPSA, HAQ) was inversely correlated with diet adherence. The most active PsA had the lowest adherence https://t.co/2Yf22zEH2o
3. Toronto longitudinal study of 1061 Psoriatic arthritis patients finds 343 had liver test abnormalities (prevalence 32%) w/ incidence rate of 39/1000 patient-years. Liver abnormalities were detected after a follow up duration of 8.3 ±7.8 years. https://t.co/FmAIJsPANu
4. CORRONA Registry - 409 biologic naive, #RA pts followed every 6 mos - at baseline half (54%) had moderate-high disease activity - yet only 29% had a change in treatment. DMARD changes more likely in your, shorter duration, high dz activity/pain/fatigue https://t.co/VNCgANkby9
5. What kind of shoes do Doctors (M/F) prefer? Survey of 225 physicians: 1) 30% casual/loafers ; 2) 25% Dress; 3) 20% Sneakers; 4) 11% Crocs/Clogs. 83% said comfort was most important. Popular brands: Clarks Dansko Skechers ECCO Merrell Rockport Cole Haan https://t.co/AvGYTJKaSG
6. #RA study shows that from 2014 to 2018, the number of malignant tumors that could be treated with immune checkpoint inhibitors has grown from 0 to 7%. Knowledge of ICI immune related adverse events is essential for rheumatologists https://t.co/bwRYRBl4PE
7. The Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) has recommended marketing authorization for upadacitinib (Rinvoq) for the treatment of rheumatoid arthritis #RA. https://t.co/xnun9oiO9q
8. THe European Medicines Agency committee announced a positive opinion recommending romosozumab for the treatment of severe osteoporosis in postmenopausal women at high Fracture risk for fracture w/ no hx of MI/CVA https://t.co/sr7iPaSngj
9. FDA Approves Ustekinumab for Ulcerative Colitis 
10. FDA Issues Boxed Warning and Recommendations for Breast Implant Use   
11. Pain Persists Despite TNF Inhibitor Use  
12. Voluntary Recall of Zantac by Sanofi/FDA